Clinical trials: Pulmonary Tuberculosis
Covid-19 Pandemics, Tuberculosis
Immunogenicity of COVID-19 Vaccines in Tuberculosis Patients
This study is a non-randomized observation and comparison of immune response between bacteriologically confirmed TB patients under treatment cohort who received COVID-19 vaccine (n=54) vs healthy individuals (n=54).
- Trial name
- CVTB (NCT05571735)
- Testing
- Pfizer-BioNTech COVID-19 vaccine, AstraZeneca vaccine, Janssen Ad26.COV2.S COVID-19 vaccine
- Where
- Thailand
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Tuberculosis, Pulmonary, Rifampicin Resistant Tuberculosis
GeneXpert Performance Evaluation for Linkage to Tuberculosis Care
The investigators' overall objective is to assess the effectiveness, implementation and costs of a streamlined TB diagnostic evaluation strategy based around rapid, onsite molecular testing.
- Trial name
- XPEL-TB (NCT03044158)
- Testing
- GeneXpert I, Process re-design, Performance Feedback
- Where
- 20 sites in Uganda
- Volunteers
- 10,644 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Tuberculosis, Pulmonary
EBA, Safety and Tolerability of Sanfetrinem Cilexetil
To evaluate the 2-week bactericidal activity, pharmacokinetics, safety and tolerability of sanfetrinem cilexetil in participants with rifampicin-susceptible pulmonary tuberculosis.
- Trial name
- NCT05388448
- Testing
- Sanfetrinem Cilexetil, Rifampicin
- Where
- South Africa
- Volunteers
- 54 people
- Sponsor
- TASK Applied Science
TB - Tuberculosis, Silicosis
KAP TB in Senior Management Officials of Companies With Increased Silica Exposure
The study was designed as a descriptive cross-sectional survey conducted between February and October 2022. Senior management officials were targeted because of their role in workplace policy and oversight.
- Conditions
- TB - Tuberculosis, Silicosis, Occupational Exposure, Occupational Health
- Trial name
- KAP TB (NCT07749872)
- Where
- Zambia
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- Centre for Infectious Disease Research in Zambia
Tuberculosis, Diagnoses Disease
TB-CAPT CORE Truenat Trial
A cluster randomized controlled trial to evaluate the effect of placing Truenat platform/TB assays at primary health care clinics combined with rapid communication of results on time to treatment initiation of microbiologically…
- Trial name
- NCT04568954
- Testing
- Truenat TB platform/TB assays
- Where
- 4 sites in Mozambique, Tanzania
- Volunteers
- 3,987 people
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
Pulmonary Tuberculosis
Pharmacokinetic Study for Anti-tuberculosis Drugs
The purpose of this study is to evaluate the effect of food on pharmacokinetic profile of multiple doses orally administered first-line anti-tuberculosis drugs in subjects with pulmonary tuberculosis.
- Trial name
- TBPK (NCT00948077)
- Testing
- Rifater and EMB
- Where
- Taiwan
- Volunteers
- 16 people
- Sponsor
- Taipei Medical University WanFang Hospital
Tuberculosis Diagnosis
Plasma MTB cfDNA Before Bronchoscopy
Tuberculosis (TB) remains a major global health challenge, affecting over 10 million people annually. Hong Kong carries an intermediate TB burden, with ~3,200 new cases reported yearly.
- Trial name
- NCT07230457
- Testing
- Diagnostic Test: Plasma MTB cfDNA assay
- Where
- Hong Kong
- Volunteers
- 600 people
- Sponsor
- Chinese University of Hong Kong
Haemoptysis
Endobronchial Valves in Inoperable Patients With Haemoptysis
Massive haemoptysis is a life-threatening condition which is commonly seen in patients who have previously had pulmonary tuberculosis.
- Trial name
- NCT02816229
- Testing
- Insertion of endobronchial valve
- Volunteers
- 20 people
- Sponsor
- University of Stellenbosch
Tuberculosis, Pulmonary
Shortened Regimens for Drug-susceptible Pulmonary Tuberculosis
The purpose of the study is to evaluate the safety and efficacy of two shortened regimens for newly diagnosed smear positive drug susceptible pulmonary tuberculosis in comparison to World Health Organization recommended standard…
- Trial name
- NCT02901288
- Testing
- Isoniazid, Rifampicin, Pyrazinamide
- Where
- 35 sites in China
- Volunteers
- 3,900 people
- Sponsor
- Beijing Chest Hospital
TB, COVID-19
Evaluation of the Truenat™MTB Plus/COVID-19 Test for TB (Tuberculosis) and COVID-19 (SARS-CoV2)
This is a prospective, multicentre study in which the accuracy of the Molbio Diagnostics Truenat™ MTB (Mycobacterium tuberculosis) Plus/COVID-19multiplex will be assessed for TB and COVID-19 case detection using prospectively…
- Trial name
- Truenat COMBO (NCT05405296)
- Testing
- Truenat™ MTB Plus/COVID-19
- Where
- Uganda
- Volunteers
- 1,984 people
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
Pulmonary Tuberculosis
Efficacy and Safety of Isoniazid, Rifampicin and Moxifloxacin for the Intensive Phase of Initial Therapy of PTB
This study aims to find an optimized initial regimen for pulmonary tuberculosis(PTB), evaluating the efficacy, safety and acceptability of isoniazid, rifampicin and moxifloxacin(HRM) for the intensive phase of initial therapy of…
- Trial name
- NCT04187469
- Testing
- Moxifloxacin, Isoniazid, Rifampicin, Rifampicin,Isoniazid,Pyrazinamide,Ethambutol
- Where
- China
- Volunteers
- 286 people
- Sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University
Tuberculosis, Pulmonary
Post TB Sequelae Study
The goal of this prospective cohort study is to learn about the long-term health effects of tuberculosis (TB) in children, adolescents, and adults who have completed standard TB treatment in Bangladesh.
- Trial name
- NCT06744179
- Testing
- echocardiography, chest x-ray, full blood count , SGPT, lipid profile, HbA1C, AQ20 questionnaire, mmRC dyspnoea scale, Duke activity status index, COPD assessment test, Age and stage questionnaire
- Where
- Bangladesh
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Tuberculosis, Pulmonary
Evaluation of PET/MRI Using a Somatostatin Analog Tracer as a Novel Approach to Detecting Pathology in High Risk TB-exposed Contacts
PET/MRI (positron emission tomography/magnetic resonance imaging) with somatostatin analog tracers has the potential to provide an imaging technique targeting subclinical granulomatous disease in those with latent tuberculosis…
- Trial name
- NCT02967666
- Testing
- FDG ligand, DOTANOC ligand
- Where
- 2 sites in Singapore
- Volunteers
- 30 people
- Sponsor
- National University Hospital, Singapore
Type 2 Diabetes Mellitus, Pulmonary Tuberculosis
Effect of Supplementary Vitamin D in Patients With Diabetes Mellitus and Pulmonary Tuberculosis
Pakistan ranks fifth amongst high tuberculosis-(TB) burden countries, where TB persists as a major cause of misery and death. The Diabetes Mellitus-(DM) is also on rise in Pakistan and people suffering from DM are more prone to…
- Trial name
- EVIDENT (NCT02169570)
- Testing
- Vitamin D, Calcium
- Where
- Pakistan
- Volunteers
- 435 people
- Sponsor
- Dow University of Health Sciences
Pulmonary Tuberculosis
A Clinical Trial to Study the Effect of the Addition of Vitamin D to Conventional Treatment in New Pulmonary Tuberculosis Patients
There is some evidence that supplemental Vitamin D may contribute to quicker recovery from TB when given in addition to normal TB therapy. This needs to be proven with a controlled clinical trial.
- Trial name
- NCT00366470
- Testing
- A. 100,000 IU Cholecalciferol per dose of 3.3ml, B. Migliol Oil without Cholecalciferol
- Where
- 2 sites in India
- Volunteers
- 250 people
- Sponsor
- Peter Daley
Hay Fever, Asthma
Evaluating the Potential of Large Language Models for Respiratory Disease Consultations
The clinical trial aimes to evaluate multiple large language models in respiratory disease consultations by comparing their performance to that of human doctors across three major medical consultation scenarios.
- Conditions
- Hay Fever, Asthma, Acute Upper Respiratory Infection, Pulmonary Embolism
- Trial name
- EPLLMMRDC (NCT06457269)
- Testing
- Diagnosis by three human doctors, Diagnosis by ChatGPT-3.5 (with search capabilities), Diagnosis by ChatGPT-3.5 (without search capabilities)
- Where
- China
- Volunteers
- 703 people
- Sponsor
- North Sichuan Medical College
Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant
PredictEndTB Signature for Individualizing Treatment in Multidrug-Resistant Tuberculosis
PredictEndTB signature is a non-inferiority, prospective, parallel-group open-label randomized controlled trial evaluating the efficacy of individualised antituberculous treatment durations that utilize the transcriptomic…
- Conditions
- Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant, Bacterial Infections, Mycobacterial Infection
- Trial name
- NCT04783727
- Testing
- Individualised treatment duration based on RNA transcriptomic model
- Where
- 5 sites in Germany, Moldova and 2 more
- Volunteers
- 4 people
- Sponsor
- Research Center Borstel
Tuberculosis, Pulmonary, HIV
Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible Tuberculosis
The PRESCIENT trial is a Phase IIc, open-label, randomized trial that compared a 12-week regimen of bedaquiline (BDQ), clofazimine (CFZ), pyrazinamide (PZA), and delamanid (DLM) with standard treatment for drug-susceptible…
- Trial name
- PRESCIENT (NCT05556746)
- Testing
- Bedaquiline (BDQ), Clofazimine (CFZ), Pyrazinamide (PZA)
- Where
- 2 sites in Haiti, South Africa
- Volunteers
- 94 people
- Sponsor
- Brigham and Women's Hospital
Pulmonary Tuberculosis
Efficacy and Safety of Qinbudan as an Adjunct Therapy for Retreatment Pulmonary Tuberculosis
The purpose of this study is to assess the efficacy and safety of Chinese medicine Qinbudan in Patients Receiving Standard Combination Therapy for Retreatment Pulmonary Tuberculosis.
- Trial name
- NCT02313610
- Testing
- Qinbudan
- Where
- 12 sites in China
- Volunteers
- 253 people
- Sponsor
- Shanghai University of Traditional Chinese Medicine
Tuberculosis, Inflammation Biomarkers
Effects of Adjunct Omega-3 Long Chain Polyunsaturated Fatty Acids in Pulmonary Tuberculosis Patient: an Early Bactericidal Activity and Inflammatory Trial
The goal of this randomized controlled trial is to evaluate the early bactericidal activity, early inflammatory response, and safety of omega-3 long chain polyunsaturated fatty acid (n-3 PUFA) supplementation in adult patients…
- Conditions
- Tuberculosis, Inflammation Biomarkers, Liver Function Tests, Iron Status
- Trial name
- TREAT 3 (NCT07118059)
- Testing
- Omega-3 (EPA+DHA)
- Where
- South Africa
- Volunteers
- 40 people
- Sponsor
- North-West University, South Africa